Disclosures for "Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Patients with Spinal Muscular Atrophy Type 1")
-
Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received research support from Sarepta.
-
Dr. Wigderson has received personal compensation for serving as an employee of Novartis Gene Therapies. Dr. Wigderson has stock in Novartis.
-
Dr. Alecu has stock in Novartis.
-
Dr. Yang has nothing to disclose.
-
Lesa Mehl has received personal compensation for serving as an employee of AveXis / Novartis Gene Therapies / Novartis Institutes for Biomedical Research, Inc. Lesa Mehl has stock in Novartis.
-
Dr. Connolly has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech Roche. Dr. Connolly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Edgewise Therapeutics. Dr. Connolly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Connolly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Octapharma. Dr. Connolly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis.